Market Overview

UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds Continue


In a report published Thursday, Bank of America analyst Steve Byrne downgraded the rating on Theravance (NASDAQ: THRX) from Buy to Neutral, and lowered the price target from $34.00 to $31.00.

In the report, Bank of America noted, “Following comments from GSK on its 2Q14 results call on continued pressure on the branded COPD market from competitor discounting (resulting in challenging formulary coverage), we lowered our near and longer term sales expectations for Breo/Relvar and Anoro. Our caution is based on our view that higher discounting than we anticipated for all respiratory products is unlikely to meaningfully improve. Our changes resulted in a $3 impact to our NPV. We lower our rating to Neutral.”

Theravance closed on Wednesday at $25.32.

Latest Ratings for THRX

May 2015Cowen & Co.DowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014StifelDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings


Related Articles (THRX)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Downgrades Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at